blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3013850

EP3013850 - GLYCOGEN SYNTHASE KINASE-3 INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.05.2019
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  22.06.2018
FormerGrant of patent is intended
Status updated on  21.01.2018
FormerExamination is in progress
Status updated on  03.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Ramot at Tel-Aviv University Ltd.
P.O. Box 39296
6139201 Tel-Aviv / IL
For all designated states
Yeda Research and Development Co. Ltd.
at the Weizmann Institute of Science
P.O. Box 95
7610002 Rehovot / IL
[2018/08]
Former [2016/18]For all designated states
Ramot at Tel-Aviv University Ltd.
P.O. Box 39296
6139201 Tel-Aviv / IL
For all designated states
Yeda Research and Development Co., Ltd.
at the Weizmann Institute of Science
P.O. Box 95
7610002 Rehovot / IL
Inventor(s)01 / ELDAR-FINKELMAN, Hagit
61 Emek Ayalon Street
6083561 Shoham / IL
02 / EISENSTEIN, Miriam
7 Paldi Street
7624807 Rehovot / IL
03 / LICHT-MURAVA, Avital
73 Einstein Street
6910226 Tel-Aviv / IL
 [2016/18]
Representative(s)Straus, Alexander, et al
Patentanwälte
Becker, Kurig, Straus
Bavariastrasse 7
80336 München / DE
[2018/30]
Former [2016/18]Dennemeyer & Associates S.A.
Poccistrasse 11
80336 München / DE
Application number, filing date14736462.424.06.2014
[2016/18]
WO2014IL50567
Priority number, dateUS201361838347P24.06.2013         Original published format: US 201361838347 P
[2016/18]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014207743
Date:31.12.2014
Language:EN
[2014/53]
Type: A2 Application without search report 
No.:EP3013850
Date:04.05.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 31.12.2014 takes the place of the publication of the European patent application.
[2016/18]
Type: B1 Patent specification 
No.:EP3013850
Date:25.07.2018
Language:EN
[2018/30]
Search report(s)International search report - published on:EP26.03.2015
ClassificationIPC:C07K7/06, C07K7/08
[2016/18]
CPC:
C07K7/08 (EP,US); C07K7/06 (US); A61K38/095 (EP,US);
A61K38/10 (EP,US); G16B15/00 (EP,US); G16B15/30 (EP,US);
G16B35/00 (EP,US); G16B35/20 (EP,US); G16C20/60 (EP,US);
A61K38/00 (EP,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/18]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:GLYCOGENSYNTHASEKINASE-3-INHIBITOREN[2016/18]
English:GLYCOGEN SYNTHASE KINASE-3 INHIBITORS[2016/18]
French:INHIBITEURS DE GLYCOGÈNE SYNTHASE KINASE-3[2016/18]
Entry into regional phase22.01.2016National basic fee paid 
22.01.2016Designation fee(s) paid 
22.01.2016Examination fee paid 
Examination procedure22.01.2016Examination requested  [2016/18]
05.09.2016Amendment by applicant (claims and/or description)
07.02.2017Despatch of a communication from the examining division (Time limit: M06)
17.08.2017Reply to a communication from the examining division
07.09.2017Despatch of a communication from the examining division (Time limit: M04)
16.11.2017Reply to a communication from the examining division
22.01.2018Communication of intention to grant the patent
09.05.2018Fee for grant paid
09.05.2018Fee for publishing/printing paid
09.05.2018Receipt of the translation of the claim(s)
Opposition(s)26.04.2019No opposition filed within time limit [2019/27]
Fees paidRenewal fee
27.06.2016Renewal fee patent year 03
29.06.2017Renewal fee patent year 04
18.06.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.06.2014
AL25.07.2018
AT25.07.2018
CY25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
MK25.07.2018
MT25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
PT25.11.2018
[2022/31]
Former [2021/34]HU24.06.2014
AL25.07.2018
AT25.07.2018
CY25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
MT25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
PT25.11.2018
Former [2021/32]HU24.06.2014
AL25.07.2018
AT25.07.2018
CY25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
PT25.11.2018
Former [2021/26]AL25.07.2018
AT25.07.2018
CY25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
PT25.11.2018
Former [2020/29]AL25.07.2018
AT25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
PT25.11.2018
Former [2020/16]AL25.07.2018
AT25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
TR25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2020/08]AL25.07.2018
AT25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
MC25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/37]AL25.07.2018
AT25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SI25.07.2018
SK25.07.2018
SM25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/26]AL25.07.2018
AT25.07.2018
CZ25.07.2018
DK25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SK25.07.2018
SM25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/23]AL25.07.2018
AT25.07.2018
CZ25.07.2018
EE25.07.2018
ES25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
SK25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/22]AL25.07.2018
AT25.07.2018
CZ25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RO25.07.2018
RS25.07.2018
SE25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/21]AL25.07.2018
AT25.07.2018
FI25.07.2018
HR25.07.2018
IT25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RS25.07.2018
SE25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/12]AL25.07.2018
AT25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
LV25.07.2018
NL25.07.2018
PL25.07.2018
RS25.07.2018
SE25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/11]AT25.07.2018
FI25.07.2018
HR25.07.2018
LT25.07.2018
NL25.07.2018
PL25.07.2018
RS25.07.2018
SE25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/10]AT25.07.2018
FI25.07.2018
LT25.07.2018
NL25.07.2018
PL25.07.2018
RS25.07.2018
SE25.07.2018
BG25.10.2018
NO25.10.2018
GR26.10.2018
IS25.11.2018
Former [2019/08]FI25.07.2018
LT25.07.2018
NL25.07.2018
NO25.10.2018
IS25.11.2018
Former [2019/07]LT25.07.2018
NL25.07.2018
Former [2019/04]NL25.07.2018
Cited inInternational search[ID]WO2004052404  (UNIV TEL AVIV FUTURE TECH DEV [IL], et al) [ID] 1-32,34-37,39-50,56 * Abstract; claims; p.14, l. 15 *;
 [ID]WO2012101599  (UNIV RAMOT [IL], et al) [ID] 1-32,34-37,39-50,56* Abstract; claims; p. 3, l. 2; p. 53, l. 10-p. 55, l. 9. *
ExaminationWO0149709
 WO2004108948
 WO2005012329
 WO2011149909
by applicantUS5013830
 US5149797
 US5220007
 US5256775
 US5366878
 US5403711
 US5491133
 US5565350
 US5623065
 US5652355
 US5652356
 WO9741854
 US5700922
 WO9816528
 US5861266
 WO0149709
 US6326174
 US2002147146
 WO2004052404
 US6780625
 WO2005000192
 US7378432
 WO2012101599
 WO2012101601
    - BHAT ET AL., J. NEUROCHEM., (2004), vol. 89, pages 1313 - 7
    - COHEN, P.; GOEDERT, M., NAT. REV. DRUG DISCOV., (2004), vol. 3, pages 479 - 87
    - MEIJER ET AL., TRENDS PHARMACOL SCI, (2004), vol. 25, pages 471 - 80
    - ELDAR-FINKELMAN ET AL., BIOCHIM BIOPHYS ACTA, vol. 1804, pages 598 - 603
    - MARTINEZ, A.; PEREZ, D. I., J. ALZHEIMERS DIS., (2008), vol. 15, pages 181 - 91
    - KERKELA ET AL., J. CLIN. INVEST., (2008), vol. 118, pages 3609 - 18
    - DROUCHEAU ET AL., BBRC, (2004), vol. 1700, pages 139 - 140
    - OJO ET AL., ANTIMICROB AGENTS CHEMOTHER, (2008), pages 37107 - 3717
    - WRAY ET AL., BIOCHEM SOC TRANS, (2010), pages 1027 - 32
    - PLOTKIN ET AL., J. PHARMACOL. EXP. THER., (2003), pages 974 - 980
    - WOODGETT; COHEN, BIOCHIM. BIOPHYS. ACTA, (1984), vol. 788, pages 339 - 47
    - FIOL ET AL., J. BIOL. CHEM., (1987), vol. 262, pages 14042 - 8
    - DAJANI ET AL., CELL, (2001), vol. 105, pages 721 - 32
    - TER HAAR ET AL., NATURE STRUCTURAL BIOLOGY, (2001), vol. 8, pages 593 - 6
    - KAIDANOVICH-BEILIN; ELDAR-FINKELMAN, J. PHARMACOL. EXP. THER., (2005), vol. 316, pages 17 - 24
    - RAO ET AL., DIABETOLOGIA, (2007), vol. 50, pages 452 - 60
    - KIM ET AL., NEURON, (2006), vol. 52, pages 981 - 96
    - CHEN ET AL., FASEB J, (2004), vol. 18, pages 1162 - 4
    - KAIDANOVICH-BEILIN ET AL., BIOL. PSYCHIATRY, (2004), vol. 55, pages 781 - 4
    - SHAPIRA ET AL., MOL. CELL NEUROSCI., (2007), vol. 34, pages 571 - 7
    - ILOUZ ET AL., J. BIOL. CHEM., (2006), vol. 281, pages 30621 - 30
    - LICHT-MURAVA ET AL., J. MOL. BIOL., (2011), vol. 408, pages 366 - 378
    - LIBERMAN, Z.; ELDAR- FINKELMAN, H., J. BIOL. CLIENT., (2005), vol. 280, pages 4422 - 8
    - LIBERMAN ET AL., AM. J. PHYSIOL. ENDOCRINOL. METAB., (2008), vol. 294, pages E1169 - 77
    - BERTRAND ET AL., J. MOL. BIOL., (2003), vol. 333, pages 393 - 407
    - PALOMO ET AL., J. MED. CHEM., (20120223), vol. 55, no. 4, pages 1645 - 61
    - KAIDANOVICH-BEILIN; ELDAR-FINKELMAN, J. PHARMACOL. EXP. THER., (2005), vol. 3.16, pages 17 - 24
    - LIBERMAN, Z.; ELDAR-FINKELMAN, H., J. BIOL. CHENI., (2005), vol. 280, pages 4422 - 8
    - LIBERMAN ET AL., AM. J. PHYSIOL. ENDOCRINOL. METAB., (2008), vol. 294, pages 169 - 77
    - CARSON, M., METHODS IN ENZYMOLOGY, (1997), vol. 277, page 25
    - JONES, TA. ET AL., ACTA CRYSTALLOGR, (1991), vol. A47, page 110
    - KRAULIS, J., APPL CRYSTALLOGR., (1991), vol. 24, page 946
    - MUNSHI CB; GRAEFF R; LEE HC, J BIOL CHENI, (20021220), vol. 277, no. 51, pages 49453 - 8
    - HUTVAGNER; ZAMORE, CURR. OPIN. GENETICS AND DEVELOPMENT, (2002), vol. 12, pages 225 - 232
    - SANTORO, S.W.; JOYCE, G.F., PROC. NATL, ACAD. SCI. USA, page 199
    - KHACHIGIAN, LM CURR OPIN MOL THER, (2002), vol. 4, pages 119 - 21
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO.
    - FINGL ET AL., The Pharmacological Basis of Therapeutics, (1975), page L
    - RADHAKRISHNAN ET AL., CELL, (1997), vol. 91, no. 6, pages 741 - 752
    - VAN DER SPOEL, J. COMPUT. CHENI., (2005), vol. 26, pages 1701 - 18
    - LINDAHL ET AL., JOURNAL OF MOLECULAR MODELING, (2001), vol. 7, no. 8, pages 306 - 317
    - BERCHANSKI ET AL., PROTEINS, (2004), vol. 351, pages 309 - 26
    - KOWALSMAN; EISENSTEIN, PROTEINS, (2009), vol. 77, pages 297 - 318
    - SAURA ET AL., J. NEUROSCI., (2005), vol. 25, no. 29, pages 6755 - 6764
    - OAKLEY ET AL., J. NEUROSCI., (2006), vol. 26, no. 40, pages 10129 - 10140
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.